Harvoni Shows Success Against Uncommon HCV Variants

A treatment approved for the most common form of hepatitis C in the US was also highly effective in less widespread variants, researchers reported at the European Association for the Study of the Liver annual meeting.

A treatment approved for the most common form of hepatitis C (HCV) in the US was also highly effective in less widespread variants, researchers reported.

The 2-drug single-pill combination of sofosbuvir and ledipasvir (Harvoni) is indicated in the U.S. for genotype 1 HCV infection, noted Armand Abergel, MD, PhD, of the Hopital d'Estaing in Clermont-Ferrand, France, and colleagues.

But in an open-label study among patients with genotypes 4 and 5 disease, the combination yielded efficacy results that were similar to those seen in genotype 1, Dr Abergel reported in a plenary session at the European Association for the Study of the Liver annual meeting.

Read more at MedPage Today: http://bit.ly/1b6xuWA